HEXASODIUM PHYTATE

HEXASODIUM PHYTATE

cas 34367-89-0

myo-Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate) sodium salt (1:6)

hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate

free form RN: 83-86-3

C₆H₁₂Na₆O₂₄P₆, 791.93

• Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo– (8CI)
• myo-Inositol, hexakis(dihydrogen phosphate), hexasodium salt (9CI)
• Hexasodium fytate
• Hexasodium phytate
• SNF 472
• UNII-ZBX50UG81V
• CSL-525; Hexasodium phytate; Myo-inositol hexaphosphate; SNF-472

x Na salt

14306-25-3

C₆H₁₈O₂₄P₆.xNa

free form : 83-86-3

myo-Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate), sodium salt

(1R,2R,3S,4S,5R,6S)-CYCLOHEXANE-1,2,3,4,5,6-HEXAYL-HEXAKIS(DIHYDROGEN PHOSPHATE)

• Inositol, hexakis(dihydrogen phosphate) sodium salt, myo– (8CI)
• myo-Inositol, hexakis(dihydrogen phosphate), sodium salt (9CI)
• Inositol hexaphosphate sodium salt
• Phytic acid sodium salt
• Sodium inositol hexaphosphate
• Sodium phytate

• OriginatorLaboratoris Sanifit
• DeveloperCSL Vifor; Laboratoris Sanifit
• ClassAntineoplastics; Calcium regulators; Cardiovascular therapies; Phosphates; Small molecules; Sodium compounds; Sugar alcohols
• Mechanism of ActionUndefined mechanism
• Orphan Drug StatusYes – Peripheral arterial disorders; Calciphylaxis
• Phase IIICalciphylaxis; Peripheral arterial disorders
• 09 Nov 2022Phase-III clinical trials in Peripheral arterial disorders in USA (IV) (CSL Behring pipeline, November 2022)
• 24 Oct 2022Sanifit Therapeutics completes a phase III trial in Calciphylaxis in Belgium, Poland, United Kingdom, Germany, Spain, USA (IV) (NCT04195906)
• 28 Sep 2022Hexasodium fytate is still in phase III trials for Calciphylaxis in USA (IV) (NCT04195906)
• You need to be a logged in or subscribed to view this 

Hexasodium phytate (also known as SNF472) is a compound being developed as a potential treatment for calciphylaxis, a condition causing skin damage and tissue death in patients with end-stage renal disease. It works by inhibiting the formation and growth of hydroxyapatite crystals, which are implicated in calciphylaxis. 

What it is:Hexasodium phytate is the hexasodium salt of myo-inositol hexaphosphate (IP6), a naturally occurring substance found in foods like beans and grains. 

• How it works:It binds to hydroxyapatite crystals, the main component of vascular calcification, and prevents their growth, potentially disrupting the calciphylaxis process. 
• Why it’s used:Hexasodium phytate is being investigated as a treatment for calciphylaxis, a serious complication of end-stage renal disease characterized by skin and tissue damage due to calcification of small blood vessels. 
• Mechanism:It is believed to work by inhibiting the formation and growth of calcium-phosphate crystals (hydroxyapatite) in the blood vessels, thus preventing the calcification that leads to calciphylaxis. 
• Clinical trials:Clinical trials have demonstrated the safety and potential efficacy of hexasodium phytate in reducing hydroxyapatite crystallization in patients undergoing hemodialysis, providing a basis for its use in treating calciphylaxis. 
• Intravenous administration:It is administered intravenously during dialysis sessions to achieve supra-physiological plasma concentrations, which are thought to be necessary for its therapeutic effect. 
• Benefits:It has shown promise in preclinical studies and clinical trials, potentially improving wound healing, pain, and health-related quality of life in patients with calciphylaxis. 
• Active development:It is currently in active development as a novel experimental drug for the treatment of calciphylaxis and other related conditions. 

Phytic acid is a major phosphorus storage compound of most seeds and cereal grains. It has the strong ability to chelate multivalent metal ions, especially zinc, calcium, and iron. Phytic acid is also considered to be a natural antioxidant and is suggested to have potential functions of reducing lipid peroxidation and as a preservative in foods. Clathrin-associated adaprot complex AP-2 has it been suggested may act as one of the receptor sites for Phytic acid. Both in vivo and in vitro experiments have demonstrated striking anticancer (preventive as well as therapeutic) effects of Phytic acid.

SCHEME

contd………

References

WO2022129148

EP4015494

CN114874473

iScience (2022), 25(3), 103950

CN111718463 

 CN110483240

Uzbekskii Khimicheskii Zhurnal (1995), (5-6), 72-75 JP61056142

////////HEXASODIUM PHYTATE, Hexasodium fytate, Hexasodium phytate, SNF 472, calciphylaxis, UNII-ZBX50UG81V, CSL-525, Hexasodium phytate, Myo-inositol hexaphosphate, SNF-472, ORPHAN DRUG